Thu, November 3, 2022

Terence Flynn Maintained (BPMC) at Strong Buy with Decreased Target to $108 on, Nov 3rd, 2022

Terence Flynn of Goldman Sachs, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Decreased Target from $143 to $108 on, Nov 3rd, 2022.

Terence has made no other calls on BPMC in the last 4 months.



There are 12 other peers that have a rating on BPMC. Out of the 12 peers that are also analyzing BPMC, 4 agree with Terence's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $52 on, Wednesday, November 2nd, 2022
  • Matthew Biegler of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, November 2nd, 2022
  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $75 on, Wednesday, November 2nd, 2022
  • Peter Lawson of "Barclays" Maintained at Hold with Decreased Target to $58 on, Wednesday, November 2nd, 2022


These are the ratings of the 8 analyists that currently disagree with Terence


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $70 on, Wednesday, November 2nd, 2022
  • Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $106 on, Wednesday, November 2nd, 2022
  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Decreased Target to $85 on, Wednesday, November 2nd, 2022
  • Zhiqiang Shu of "Berenberg" Initiated at Strong Buy and Held Target at $90 on, Wednesday, September 14th, 2022
  • Eun Yang of "Jefferies" Maintained at Strong Buy with Increased Target to $84 on, Monday, August 22nd, 2022
  • Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $100 on, Thursday, August 18th, 2022
  • Derek Archila of "Wells Fargo" Maintained at Sell with Increased Target to $41 on, Wednesday, August 17th, 2022
  • Dane Leone of "Raymond James" Maintained at Strong Buy with Decreased Target to $115 on, Wednesday, August 3rd, 2022